MedTrace Logo

A Study to Investigate the Effects of JMKX003142 on QTc Interval in Healthy Adults

NCT07470177 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-03-13

No results posted yet for this study

Summary

The primary objective of this study is to assess the effect of a therapeutic and supratherapeutic oral dose of JMKX003142 on the corrected cardiac QT interval relative to a placebo in healthy participants

Conditions

  • ADPKD (Autosomal Dominant Polycystic Kidney Disease)

Interventions

DRUG

JMKX003142 tablets

Participants will receive single of JMKX003142 6mg

DRUG

JMKX003142 tablets

Participants will receive single of JMKX003142 30mg

DRUG

Placebo

Participants will receive single of Placebo

Sponsors & Collaborators

  • Zhejiang Hangyu Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • Jemincare

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-03-27
Primary Completion
2026-05-14
Completion
2026-06-23

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07470177 on ClinicalTrials.gov